CNS Lymphoma Clinical Trial
Official title:
Comparison of Creatinine Clearance Calculation Methods for Estimation of Glomerular Filtration Rate in Patients Receiving High-Dose Methotrexate
The purpose of this study is to compare different estimates of calculating creatinine clearance by mathematical formula and compare them to creatinine clearance based on a timed urine collection in patients who received high-dose methotrexate for the treatment of primary CNS lymphoma or CNS involvement of systemic lymphoma.
We intend to perform a retrospective chart review to identify a serum creatinine-based
equation that gives the best estimate of CrCl as compared with an equation derived from a
24-hour urine collection.
Study subjects will be identified using the Brigham and Women's Hospital and Dana-Farber
Cancer Institute's Adult Pharmacy systems to identify patients who received high-dose
methotrexate. Data will be collected starting with December 31, 2010 and proceeding
chronologically backwards until the target enrollment of 40 patients is reached.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05117814 -
Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma
|
N/A | |
| Terminated |
NCT05222269 -
[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients
|
Phase 2 | |
| Recruiting |
NCT06132737 -
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT05242146 -
GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma
|
Phase 1 | |
| Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
| Recruiting |
NCT05351593 -
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05828628 -
CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
|
||
| Completed |
NCT01182415 -
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06343311 -
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04841434 -
A Phase I/II Study to Investigate the Use of VORAXAZE™ as Intended Intervention in Patients With CNSL
|
Phase 1/Phase 2 | |
| Completed |
NCT01083342 -
High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study
|
Phase 2 | |
| Completed |
NCT05293990 -
Usefulness of Gadovist-enhanced FLAIR Imaging
|
N/A | |
| Completed |
NCT00596154 -
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05926427 -
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
|
Phase 2 |